Sun Pharma inks global licensing pact with LIB Therapeutics for cholesterol drug Lerodalcibep
Sun Pharmaceutical Industries on Monday said it has signed an exclusive agreement with US-based LIB Therapeutics to manufacture, commercialise, and globally license Lerodalcibep in all markets outside the United States and China.Lerodalcibep is a once-monthly PCSK9 inhibitor used to reduce low-dens…